norfloxacin has been researched along with Diarrhea in 39 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clinical efficacy of norfloxacin for treatment of traveler's diarrhea in 106 Finnish tourists vacationing in Morocco was evaluated during two different seasons." | 9.07 | Short-term treatment of traveler's diarrhea with norfloxacin: a double-blind, placebo-controlled study during two seasons. ( Kataja, M; Kyrönseppä, H; Mattila, L; Peltola, H; Siitonen, A; Simula, I, 1993) |
| "To evaluate the clinical and microbiologic efficacy and safety of norfloxacin for acute diarrhea." | 9.07 | Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group. ( Ekwall, E; Englund, G; Hogevik, H; Jertborn, M; Lagergren, L; Lundholm, R; Norlin, K; Söderquist, B; Strömberg, A; Wiström, J, 1992) |
| "Norfloxacin, an oral fluoroquinolone (dose 400 mg daily), was compared to a placebo in a double blinded randomized trial for the prophylaxis of travelers' diarrhea." | 9.06 | Norfloxacin for the prophylaxis of travelers' diarrhea in U.S. military personnel. ( Haberberger, RL; Hyams, KC; Scott, DA; Thornton, SA, 1990) |
| "Norfloxacin, a new quinolone carboxylic acid derivative, was compared with an identical-appearing placebo preparation in a prospective, randomized, double-blind trial for prevention of traveler's diarrhea among 120 U." | 9.06 | Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin. ( Cabada, FJ; Dupont, HL; Ericsson, CD; Johnson, PC; Morgan, DR, 1986) |
| "Although theoretically the spectrum of antimicrobial quinolone antibiotics are at low risk of producing Clostridium difficile overgrowth and diarrhea, a patient developed this clinical problem while receiving norfloxacin." | 7.68 | Clostridium difficile-associated diarrhea after norfloxacin. ( Craig, RM; Ehrenpreis, ED; Lievens, MW, 1990) |
| "Both norfloxacin and TMP/SMX were clinically effective in the treatment of travelers' diarrhea in this military population." | 6.67 | Norfloxacin compared to trimethoprim/sulfamethoxazole for the treatment of travelers' diarrhea among U.S. military personnel deployed to South America and West Africa. ( Batchelor, RA; Bourgeois, AL; Burr, DH; Gardiner, C; Garst, P; Hyams, KC; Kilpatrick, ME; Oprandy, JJ; Thornton, SA; Wignall, SF, 1992) |
| "A retrospective study on the treatment of diarrhea in a U." | 5.28 | Treatment of acute diarrhea with norfloxacin during Desert Storm deployment. ( Johnson, GP; Ward, JE; Weston, TD, 1992) |
| "Ten patients with bacterial overgrowth-related diarrhea underwent the following five 7-day treatment periods: untreated (control period), then placebo, and subsequently, in random order and blinded fashion, norfloxacin (800 mg/day), amoxicillin-clavulanic acid (1500 mg/day), and Saccharomyces boulardii (1500 mg/day)." | 5.09 | Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. ( Attar, A; Bouhnik, Y; Flourié, B; Franchisseur, C; Rambaud, JC; Ruszniewski, P, 1999) |
| "To evaluate the clinical and microbiologic efficacy and safety of norfloxacin for acute diarrhea." | 5.07 | Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group. ( Ekwall, E; Englund, G; Hogevik, H; Jertborn, M; Lagergren, L; Lundholm, R; Norlin, K; Söderquist, B; Strömberg, A; Wiström, J, 1992) |
| "Norfloxacin, an oral fluoroquinolone (dose 400 mg daily), was compared to a placebo in a double blinded randomized trial for the prophylaxis of travelers' diarrhea." | 5.06 | Norfloxacin for the prophylaxis of travelers' diarrhea in U.S. military personnel. ( Haberberger, RL; Hyams, KC; Scott, DA; Thornton, SA, 1990) |
| "or t." | 3.76 | World-wide clinical experience with norfloxacin: efficacy and safety. ( Corrado, M; Hoagland, V; Sabbaj, J; Wang, C, 1986) |
| "Although theoretically the spectrum of antimicrobial quinolone antibiotics are at low risk of producing Clostridium difficile overgrowth and diarrhea, a patient developed this clinical problem while receiving norfloxacin." | 3.68 | Clostridium difficile-associated diarrhea after norfloxacin. ( Craig, RM; Ehrenpreis, ED; Lievens, MW, 1990) |
| "The pharmacokinetics of 400 mg norfloxacin administered orally were studied in 19 patients both during the acute phase of bacterial gastroenteritis and during convalescence, after normalization of bowel movements." | 3.67 | Consequences of diarrhoeal disease on the pharmacokinetics of norfloxacin. ( Bergan, T; Cheong, MK; Lolekha, S; Patancharoen, S; Poh, CL, 1988) |
| "Both norfloxacin and TMP/SMX were clinically effective in the treatment of travelers' diarrhea in this military population." | 2.67 | Norfloxacin compared to trimethoprim/sulfamethoxazole for the treatment of travelers' diarrhea among U.S. military personnel deployed to South America and West Africa. ( Batchelor, RA; Bourgeois, AL; Burr, DH; Gardiner, C; Garst, P; Hyams, KC; Kilpatrick, ME; Oprandy, JJ; Thornton, SA; Wignall, SF, 1992) |
| "When 55 patients with shigellosis (26 treated with TMP-SMX, 29 treated with norfloxacin) whose bacterial isolates were susceptible to the antibiotic given were compared by treatment group, no significant differences were seen in days of illness (mean, 2." | 2.66 | Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim-sulfamethoxazole for acute shigellosis in adults. ( Berry, SJ; Gotuzzo, E; Guzman, M; Leon-Barua, R; Maguiña, C; Oberhelman, RA; Ruiz, R; Sack, RB; Yi, A, 1989) |
| "Norfloxacin has been compared to placebo (136 patients), sulfamethoxazole plus trimethoprim (SXT, 72 patients) and oral vancomycin plus colistin (V/C, 61 patients) for the prevention of alimentary tract-associated infections during and after induction chemotherapy." | 2.66 | The tolerability profile of prophylactic norfloxacin in neutropenic patients. ( Corrado, ML; Hesney, M; Struble, WE, 1988) |
| "Treatment with norfloxacin resulted in a significant reduction of samples yielding aerobic Gram-negative rods but did not affect enterococci." | 2.66 | Norfloxacin versus placebo for prophylaxis against travellers' diarrhoea. ( Burman, LG; Englund, G; Jellheden, B; Lundholm, R; Norrby, SR; Wiström, J, 1987) |
| "Norfloxacin has great potential for the treatment of bacterial enteric infections reflected by its broad in vitro activity as well as its effectiveness in initial clinical trials." | 2.37 | Norfloxacin in the treatment of bacterial enteric infections. ( Ruiz-Palacios, GM, 1986) |
| "A retrospective study on the treatment of diarrhea in a U." | 1.28 | Treatment of acute diarrhea with norfloxacin during Desert Storm deployment. ( Johnson, GP; Ward, JE; Weston, TD, 1992) |
| "Norfloxacin was the most active compound of those tested with MICs in the range 0." | 1.28 | In vitro activity of norfloxacin and other antibacterial agents against gastro-intestinal pathogens isolated in Sweden. ( Möllby, R; Olsson-Liljequist, B, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (38.46) | 18.7374 |
| 1990's | 19 (48.72) | 18.2507 |
| 2000's | 4 (10.26) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Do, KH | 1 |
| Seo, KW | 1 |
| Byun, JW | 1 |
| Lee, WK | 1 |
| Bustillo, I | 1 |
| Larson, H | 1 |
| Saif, MW | 1 |
| Mwachari, CW | 1 |
| Meier, AS | 1 |
| Muyodi, J | 1 |
| Gatei, W | 1 |
| Waiyaki, P | 1 |
| Cohen, CR | 1 |
| Sinha, S | 1 |
| Chattopadhyay, S | 1 |
| Bhattacharya, SK | 1 |
| Nair, GB | 1 |
| Ramamurthy, T | 1 |
| Bassily, S | 2 |
| Mikhail, I | 1 |
| Haberberger, RL | 2 |
| Zakaria, S | 1 |
| Yassa, M | 1 |
| El Masry, NA | 1 |
| Woody, JN | 1 |
| Hyams, KC | 3 |
| el-Masry, NA | 1 |
| Farid, Z | 1 |
| Cross, E | 1 |
| Bourgeois, AL | 2 |
| Ayad, E | 1 |
| Hibbs, RG | 1 |
| Mattila, L | 1 |
| Peltola, H | 1 |
| Siitonen, A | 1 |
| Kyrönseppä, H | 1 |
| Simula, I | 1 |
| Kataja, M | 1 |
| Baird, RW | 1 |
| Tadano, K | 1 |
| Shingaki, M | 1 |
| Saito, K | 1 |
| Takahashi, M | 1 |
| Kai, A | 1 |
| Yanagawa, Y | 1 |
| Itoh, T | 1 |
| Ohta, K | 1 |
| Kudoh, Y | 1 |
| Oyofo, BA | 1 |
| Peruski, LF | 1 |
| Ismail, TF | 1 |
| el-Etr, SH | 1 |
| Churilla, AM | 1 |
| Wasfy, MO | 1 |
| Petruccelli, BP | 1 |
| Gabriel, ME | 1 |
| Sjögren, E | 1 |
| Lindblom, GB | 1 |
| Kaijser, B | 1 |
| Rolland, RM | 1 |
| Chalifoux, LV | 1 |
| Snook, SS | 1 |
| Ausman, LM | 1 |
| Johnson, LD | 1 |
| Moolasart, P | 2 |
| Eampokalap, B | 2 |
| Supaswadikul, S | 1 |
| Pandya, S | 1 |
| Attar, A | 1 |
| Flourié, B | 1 |
| Rambaud, JC | 1 |
| Franchisseur, C | 1 |
| Ruszniewski, P | 1 |
| Bouhnik, Y | 1 |
| Ratanasrithong, M | 1 |
| Stahlmann, R | 1 |
| Johnson, GP | 1 |
| Weston, TD | 1 |
| Ward, JE | 1 |
| Thornton, SA | 2 |
| Wignall, SF | 1 |
| Kilpatrick, ME | 1 |
| Gardiner, C | 1 |
| Batchelor, RA | 1 |
| Burr, DH | 1 |
| Oprandy, JJ | 1 |
| Garst, P | 1 |
| Wiström, J | 3 |
| Jertborn, M | 2 |
| Ekwall, E | 1 |
| Norlin, K | 1 |
| Söderquist, B | 1 |
| Strömberg, A | 1 |
| Lundholm, R | 2 |
| Hogevik, H | 1 |
| Lagergren, L | 1 |
| Englund, G | 3 |
| Hyslop, DL | 1 |
| Bischoff, W | 1 |
| Scott, DA | 1 |
| Olsson-Liljequist, B | 1 |
| Möllby, R | 1 |
| Ehrenpreis, ED | 1 |
| Lievens, MW | 1 |
| Craig, RM | 1 |
| Eitrem, R | 1 |
| Hedström, SA | 1 |
| Alestig, K | 1 |
| Jellheden, B | 2 |
| Norrby, SR | 2 |
| Gotuzzo, E | 1 |
| Oberhelman, RA | 1 |
| Maguiña, C | 1 |
| Berry, SJ | 1 |
| Yi, A | 1 |
| Guzman, M | 1 |
| Ruiz, R | 1 |
| Leon-Barua, R | 1 |
| Sack, RB | 1 |
| Murray, BE | 1 |
| Neu, HC | 1 |
| O'Hare, MD | 1 |
| Felmingham, D | 1 |
| Ridgway, GL | 1 |
| Grüneberg, RN | 1 |
| Lolekha, S | 2 |
| Patanachareon, S | 1 |
| Thanangkul, B | 1 |
| Vibulbandhitkit, S | 1 |
| Bergan, T | 1 |
| Cheong, MK | 1 |
| Poh, CL | 1 |
| Patancharoen, S | 1 |
| Corrado, ML | 2 |
| Struble, WE | 1 |
| Hesney, M | 1 |
| Lee, C | 1 |
| Ronald, AR | 1 |
| Dupont, HL | 2 |
| Sabbaj, J | 2 |
| Burman, LG | 1 |
| Ruiz-Palacios, GM | 1 |
| Wang, C | 1 |
| Corrado, M | 1 |
| Hoagland, V | 1 |
| Johnson, PC | 1 |
| Ericsson, CD | 1 |
| Morgan, DR | 1 |
| Cabada, FJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Retrospective Analysis of Treatment Outcomes in Patients With Bacterial Overgrowth Syndrome Diagnosed by D-Xylose Breath Testing[NCT01324895] | 944 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for norfloxacin and Diarrhea
| Article | Year |
|---|---|
Quinolones and the gastrointestinal tract.
Topics: Agranulocytosis; Anti-Infective Agents; Bacterial Infections; Biliary Tract Diseases; Diarrhea; Drug | 1989 |
Norfloxacin: its potential in clinical practice.
Topics: Bacterial Infections; Diarrhea; Gonorrhea; Humans; Neutropenia; Norfloxacin; Travel; Urinary Tract I | 1987 |
Norfloxacin in the treatment of bacterial enteric infections.
Topics: Bacterial Infections; Diarrhea; Enteritis; Humans; Norfloxacin | 1986 |
World-wide clinical experience with norfloxacin: efficacy and safety.
Topics: Acute Disease; Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Diarrhea; Gastroente | 1986 |
17 trials available for norfloxacin and Diarrhea
| Article | Year |
|---|---|
Short-course norfloxacin and trimethoprim-sulfamethoxazole treatment of shigellosis and salmonellosis in Egypt.
Topics: Adult; Aged; Developing Countries; Diarrhea; Double-Blind Method; Drug Administration Schedule; Dyse | 1994 |
Short-term treatment of traveler's diarrhea with norfloxacin: a double-blind, placebo-controlled study during two seasons.
Topics: Adolescent; Adult; Aeromonas; Aged; Campylobacter jejuni; Diarrhea; Double-Blind Method; Escherichia | 1993 |
Comparison of the efficacy of tetracycline and norfloxacin in the treatment of acute severe watery diarrhea.
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Child; Child, Pr | 1998 |
Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; | 1999 |
Comparison of the efficacy of ceftibuten and norfloxacin in the treatment of acute gastrointestinal infection in children.
Topics: Acute Disease; Anti-Infective Agents; Ceftibuten; Cephalosporins; Child; Child, Preschool; Diarrhea; | 1999 |
Norfloxacin compared to trimethoprim/sulfamethoxazole for the treatment of travelers' diarrhea among U.S. military personnel deployed to South America and West Africa.
Topics: Acute Disease; Adolescent; Adult; Africa, Western; Bacterial Infections; Diarrhea; Escherichia coli | 1992 |
Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Child; Diarrhea; Double-Blind Method; Fem | 1992 |
Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cefaclor; Cephalosporins; Diarrhea; Double-Blind Method; | 1992 |
Norfloxacin for the prophylaxis of travelers' diarrhea in U.S. military personnel.
Topics: Acute Disease; Adult; Developing Countries; Diarrhea; Egypt; Follow-Up Studies; Humans; Military Per | 1990 |
Short-term self-treatment of travellers' diarrhoea with norfloxacin: a placebo-controlled study.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Diarrhea; Double-Blind Method; Escherichia coli; | 1989 |
Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim-sulfamethoxazole for acute shigellosis in adults.
Topics: Adult; Clinical Trials as Topic; Diarrhea; Drug Combinations; Dysentery, Bacillary; Feces; Humans; N | 1989 |
Norfloxacin versus co-trimoxazole in the treatment of acute bacterial diarrhoea: a placebo controlled study.
Topics: Acute Disease; Adult; Bacterial Infections; Clinical Trials as Topic; Diarrhea; Double-Blind Method; | 1988 |
The tolerability profile of prophylactic norfloxacin in neutropenic patients.
Topics: Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Colistin; Diarrhea; Gastrointestina | 1988 |
Use of norfloxacin in the treatment of acute diarrheal disease.
Topics: Acute Disease; Adult; Child; Clinical Trials as Topic; Diarrhea; Drug Combinations; Feces; Humans; M | 1987 |
Norfloxacin versus placebo for prophylaxis against travellers' diarrhoea.
Topics: Adult; Aged; Clinical Trials as Topic; Diarrhea; Double-Blind Method; Female; Humans; Male; Microbia | 1987 |
World-wide clinical experience with norfloxacin: efficacy and safety.
Topics: Acute Disease; Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Diarrhea; Gastroente | 1986 |
Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin.
Topics: Bacteria; Diarrhea; Drug Resistance, Microbial; Feces; Humans; Norfloxacin; Travel | 1986 |
19 other studies available for norfloxacin and Diarrhea
| Article | Year |
|---|---|
Relationship between virulence factors and antimicrobial resistance genes of pathogenic Escherichia coli from diarrheic weaned piglets.
Topics: Animals; Anti-Bacterial Agents; Cefazolin; Cefoxitin; Diarrhea; Drug Resistance, Bacterial; Enteroto | 2022 |
Small intestine bacterial overgrowth: an underdiagnosed cause of diarrhea in patients with pancreatic cancer.
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteria; Blind Loop Syndrome | 2009 |
Chronic diarrhoea in HIV-1-infected adults in Nairobi, Kenya: evaluation of risk factors and the WHO treatment algorithm.
Topics: Adult; Algorithms; Anti-Infective Agents; Chronic Disease; Cohort Studies; Diarrhea; Drug Therapy, C | 2003 |
An unusually high level of quinolone resistance associated with type II topoisomerase mutations in quinolone resistance-determining regions of Aeromonas caviae isolated from diarrhoeal patients.
Topics: Aeromonas; Anti-Infective Agents; Base Sequence; Ciprofloxacin; Diarrhea; DNA Gyrase; DNA Topoisomer | 2004 |
The use of quinolones in the treatment of acute bacterial diarrhea: a comparative therapeutic trial.
Topics: Acute Disease; Adolescent; Anti-Infective Agents; Bacteria; Bacterial Infections; Chloramphenicol; D | 1989 |
Development of clinically significant resistance to norfloxacin given for Campylobacter diarrhoea.
Topics: Adult; Campylobacter; Campylobacter Infections; Diarrhea; Drug Resistance, Microbial; Female; Humans | 1993 |
[Evolution of susceptibilities of Campylobacter jejuni isolated from diarrhoeal cases to fluoroquinolones in Tokyo].
Topics: Anti-Infective Agents; Campylobacter jejuni; Ciprofloxacin; Diarrhea; Drug Resistance, Microbial; Hu | 1996 |
Enteropathogens associated with diarrhea among military personnel during Operation Bright Star 96, in Alexandria, Egypt.
Topics: Ampicillin Resistance; Animals; Anti-Infective Agents; Antigens, Bacterial; Bacterial Proteins; Blas | 1997 |
Norfloxacin resistance in Campylobacter jejuni and Campylobacter coli isolates from Swedish patients.
Topics: Adult; Anti-Infective Agents; Campylobacter coli; Campylobacter Infections; Campylobacter jejuni; Ch | 1997 |
Five spontaneous deaths associated with Clostridium difficile in a colony of cotton-top tamarins (Saguinus oedipus).
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Clostridioides difficile; Clostridium Infecti | 1997 |
Fixed drug combination of treatment of diarrhea.
Topics: Anti-Infective Agents; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Drug The | 1998 |
Clinical toxicological aspects of fluoroquinolones.
Topics: Anti-Infective Agents; Bacterial Infections; Cardiovascular Diseases; Central Nervous System Disease | 2002 |
Treatment of acute diarrhea with norfloxacin during Desert Storm deployment.
Topics: Acute Disease; Adult; Diarrhea; Egypt; Female; Humans; Male; Military Personnel; Norfloxacin; Retros | 1992 |
In vitro activity of norfloxacin and other antibacterial agents against gastro-intestinal pathogens isolated in Sweden.
Topics: Bacteria; Diarrhea; Digestive System; Drug Resistance, Microbial; Microbial Sensitivity Tests; Norfl | 1990 |
Clostridium difficile-associated diarrhea after norfloxacin.
Topics: Aged; Clostridium Infections; Diarrhea; Gastroenteritis; Humans; Male; Norfloxacin | 1990 |
[Diet and loperamide are better than norfloxacin in tourist diarrhea].
Topics: Diarrhea; Humans; Loperamide; Norfloxacin; Piperidines; Travel | 1990 |
Clinical use of the quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Diarrhea; Enoxacin; Gastrointestinal Diseases; Humans; Naphthy | 1987 |
The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.
Topics: 4-Quinolones; Aeromonas; Anti-Bacterial Agents; Anti-Infective Agents; Campylobacter fetus; Cinoxaci | 1985 |
Consequences of diarrhoeal disease on the pharmacokinetics of norfloxacin.
Topics: Adolescent; Adult; Biological Availability; Diarrhea; Gastroenteritis; Humans; Norfloxacin | 1988 |